S&P 500   4,686.75 (+2.07%)
DOW   35,719.43 (+1.40%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
S&P 500   4,686.75 (+2.07%)
DOW   35,719.43 (+1.40%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
S&P 500   4,686.75 (+2.07%)
DOW   35,719.43 (+1.40%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
S&P 500   4,686.75 (+2.07%)
DOW   35,719.43 (+1.40%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
OTCBB:AMBS

Amarantus BioScience Stock Forecast, Price & News

Add
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Receive AMBS News and Ratings via Email

Sign-up to receive the latest news and ratings for Amarantus BioScience and its competitors with MarketBeat's FREE daily newsletter.


About Amarantus BioScience

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.

Headlines

News for Amarantus Bioscience Holdings Inc
December 24, 2020 |  markets.businessinsider.com
Todos Medical CEO Releases Letter to Shareholders
September 18, 2020 |  finance.yahoo.com
Nationwide On-Site Coronavirus Testing Program
July 6, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCBB:AMBS
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Optionable
Not Optionable

Company Calendar

Last Earnings
11/23/2015
Today
12/07/2021

MarketRank

Overall MarketRank

0.88 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Amarantus BioScience (OTCBB:AMBS) Frequently Asked Questions

How were Amarantus BioScience's earnings last quarter?

Amarantus BioScience Holdings, Inc. (OTCBB:AMBS) posted its quarterly earnings results on Monday, November, 23rd. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.77) by $0.21.
View Amarantus BioScience's earnings history
.

Who are Amarantus BioScience's key executives?

Amarantus BioScience's management team includes the following people:
  • Mr. Gerald E. Commissiong, CEO, Pres & Director (Age 38)
  • Dr. John Wesley Commissiong, Chief Scientific Officer, Director & Member of Scientific Advisory Board (Age 76)
  • Mr. Robert Lewis Harris, Compliance Officer & Director (Age 77)
  • Dr. Elise Brownell, Sr. VP of Operations & Project Management
  • Aimee Boutcher, Director of Investor Relations
  • Dr. Ravi Kiron, Sr. VP of Bus. Devel. (Age 61)
  • Dr. Paula T. Trzepacz, Chief Medical Advisor to Elto Pharma and Breakthrough Diagnostics
  • Dr. Brian E. Harvey, Chief Regulatory Advisor & Member of Board of Advisors
  • Dr. Richard Kagan M.D., Chief Medical Advisor to Cutanogen Corp.
  • Dr. Owen Garrick, Corp. Advisor

What other stocks do shareholders of Amarantus BioScience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amarantus BioScience investors own include Energous (WATT), (SNY), Novavax (NVAX), Amgen (AMGN), Co-Diagnostics (CODX), Quest Diagnostics (DGX), Walt Disney (DIS), Dynavax Technologies (DVAX), Gilead Sciences (GILD) and Inovio Pharmaceuticals (INO).

What is Amarantus BioScience's stock symbol?

Amarantus BioScience trades on the OTCBB under the ticker symbol "AMBS."

How do I buy shares of Amarantus BioScience?

Shares of AMBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How many employees does Amarantus BioScience have?

Amarantus BioScience employs 12 workers across the globe.

What is Amarantus BioScience's official website?

The official website for Amarantus BioScience is www.amarantus.com.

How can I contact Amarantus BioScience?

The company can be reached via phone at 650-862-5391.


This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.